Cardiometabolic effects of antidiabetic drugs in non-alcoholic fatty liver disease.

摘要: PURPOSE Non-alcoholic fatty liver disease (NAFLD) affects about 25% of the population worldwide. NAFLD may be viewed as hepatological manifestation metabolic syndrome. Patients with syndrome due to diabetes or obesity have an increased risk cardiovascular disease. This narrative review describes cardiometabolic effects antidiabetic drugs in NAFLD. METHODS We conducted a systematic search PubMed and manually scanned bibliographies trial databases reference lists relevant articles. RESULTS Heart is leading cause death Conversely, independent factor patients suffering from associated markers atherosclerosis, ischaemic heart Additionally, cardiac dysfunction failure. There are no randomized controlled trials showing clear medical treatment on clinical outcomes However, based evidence small extrapolation evaluating type 2 diabetes, some beneficial function CONCLUSION At present, there promising potential effect for Future studies should address liver-related consequences but also aim at improving outcomes.